178 related articles for article (PubMed ID: 30156165)
21. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
22. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Bai T; Tanaka T; Yukawa K; Umesaki N
Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
[TBL] [Abstract][Full Text] [Related]
23. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
[TBL] [Abstract][Full Text] [Related]
24. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells.
Tatokoro M; Koga F; Yoshida S; Kawakami S; Fujii Y; Neckers L; Kihara K
Int J Cancer; 2012 Aug; 131(4):987-96. PubMed ID: 21964864
[TBL] [Abstract][Full Text] [Related]
25. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review.
Ciocca DR; Oesterreich S; Chamness GC; McGuire WL; Fuqua SA
J Natl Cancer Inst; 1993 Oct; 85(19):1558-70. PubMed ID: 8411230
[TBL] [Abstract][Full Text] [Related]
26. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
27. GRP78 knockdown does not affect cytotoxicity of cisplatin in ovarian cancer cells.
Kullmann M; Kotz S; Hellwig M; Kalayda GV; Metzger S; Jaehde U
Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1038-40. PubMed ID: 26521923
[No Abstract] [Full Text] [Related]
28. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review).
Wang X; Chen M; Zhou J; Zhang X
Int J Oncol; 2014 Jul; 45(1):18-30. PubMed ID: 24789222
[TBL] [Abstract][Full Text] [Related]
29. Functional redundancy of HSPA1, HSPA2 and other HSPA proteins in non-small cell lung carcinoma (NSCLC); an implication for NSCLC treatment.
Sojka DR; Gogler-Pigłowska A; Vydra N; Cortez AJ; Filipczak PT; Krawczyk Z; Scieglinska D
Sci Rep; 2019 Oct; 9(1):14394. PubMed ID: 31591429
[TBL] [Abstract][Full Text] [Related]
30. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
31. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
32. Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy.
Yun CW; Kim HJ; Lim JH; Lee SH
Cells; 2019 Dec; 9(1):. PubMed ID: 31878360
[TBL] [Abstract][Full Text] [Related]
33. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
34. Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells.
Abe T; Gotoh S; Higashi K
Biochim Biophys Acta; 1999 Apr; 1445(1):123-33. PubMed ID: 10209264
[TBL] [Abstract][Full Text] [Related]
35. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics.
Gaddameedhi S; Chatterjee S
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S61-6. PubMed ID: 20009298
[TBL] [Abstract][Full Text] [Related]
36. Suppression of heat-induced HSF activation by CDDP in human glioblastoma cells.
Matsumoto H; Hayashi S; Shioura H; Ohtsubo T; Kitai R; Ohnishi K; Hayashi N; Ohnishi T; Kano E
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):915-20. PubMed ID: 9652857
[TBL] [Abstract][Full Text] [Related]
37. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy.
Vargas-Roig LM; Gago FE; Tello O; Aznar JC; Ciocca DR
Int J Cancer; 1998 Oct; 79(5):468-75. PubMed ID: 9761114
[TBL] [Abstract][Full Text] [Related]
38. Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells.
Kishimoto S; Yasuda M; Suzuki R; Fukushima S
Biometals; 2016 Dec; 29(6):1075-1083. PubMed ID: 27787693
[TBL] [Abstract][Full Text] [Related]
39. [Establishment of cisplatin-induced multidrug resistant human epithelial ovarian cancer cell line 3AO/cDDP and its expressions of multidrug resistance proteins].
Chen J; Yang R; Liu F
Zhonghua Fu Chan Ke Za Zhi; 2000 Oct; 35(10):617-20. PubMed ID: 11372415
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Suzuki M; Endo M; Shinohara F; Echigo S; Rikiishi H
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1115-22. PubMed ID: 19280190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
